Literature DB >> 23960896

Thyroid associated orbitopathy: Understanding pathophysiology.

Imtiaz A Chaudhry1.   

Abstract

Entities:  

Year:  2010        PMID： 23960896      PMCID： PMC3729512          DOI： 10.1016/j.sjopt.2010.11.001

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN： 1319-4534


× No keyword cloud information.
  12 in total

1.  Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison J Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten P Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Thyroid       Date:  2008-03       Impact factor: 6.568

Review 2.  Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.

Authors:  Hadas Stiebel-Kalish; Eyal Robenshtok; Murat Hasanreisoglu; David Ezrachi; Ilan Shimon; Leonard Leibovici
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

3.  Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.

Authors:  Rina Bhatt; Christine C Nelson; Raymond S Douglas
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

Review 4.  Risk factors for development or deterioration of Graves' ophthalmopathy.

Authors:  Marius N Stan; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

5.  Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.

Authors:  O M Durrani; T Q Reuser; P I Murray
Journal:  Orbit       Date:  2005-06

6.  Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone.

Authors:  R Ebner; M H Devoto; D Weil; M Bordaberry; C Mir; H Martinez; L Bonelli; H Niepomniszcze
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

7.  Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy.

Authors:  H J Cao; H S Wang; Y Zhang; H Y Lin; R P Phipps; T J Smith
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

8.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26

9.  Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.

Authors:  Dinesh Khanna; Kelvin K L Chong; Nikoo F Afifiyan; Catherine J Hwang; Diana K Lee; Helene Chokron Garneau; Robert A Goldberg; Christine H Darwin; Terry J Smith; Raymond S Douglas
Journal:  Ophthalmology       Date:  2009-10-08       Impact factor: 12.079

Review 10.  Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.

Authors:  Elizabeth A Bradley; Emily W Gower; David J Bradley; Dale R Meyer; Kenneth V Cahill; Philip L Custer; David E Holck; John J Woog
Journal:  Ophthalmology       Date:  2008-02       Impact factor: 12.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.